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cn the cardiac function and heart failure category, 1,143
bstracts were submitted and 377 accepted for presentation.
or clarity, this manuscript will be divided into a number of
ifferent highlight subcategories.
echanical circulatory assist. Circulatory assist devices
ave an established role as destination therapy and a bridge
o transplantation. Mussivand (1) presented trends in sup-
ort duration over 10 years in 1,235 patients. The support
uration increased from 32 days in 1991 to 196 days in 2002
nd was greater in survivors (40 to 284 days) compared with
onsurvivors (26 to 104 days). This suggests there may be a
reater emphasis on totally implantable devices in the
uture, permitting patient discharge.
Maybaum et al. (2) examined cardiac recovery during left
entricular assist device (LVAD) support in a multicenter,
rospective study of 64 patients supported for a mean of 166
ays. After 30 days, there was significant improvement in
he left ventricular ejection fraction (LVEF) (16.6% to
5.4%), left ventricular end-diastolic diameter (LVEDD)
7.2 to 4.8 cm), and left ventricular (LV) mass (321 to
98 g). Three patients with acute heart failure underwent
xplantation, but no patients with chronic heart failure
nderwent explantation. The degree of recovery is probably
nsufficient for device explantation, except in patients with
cute heart failure.
Mechanical support in nontransplant candidates was
xamined in a retrospective review of 225 patients (3). A
ow-risk category (n 146) was defined by age 65 years,
lood urea nitrogen (BUN) 100 mg/dl, creatinine 2.5
g/dl, bilirubin 5 mg/dl, negative blood cultures, and
ulmonary vascular resistance (PVR)480 dynes  s/cm5. A
igh-risk category (n  44) was defined by one or more
iscordant values from the low-risk group. The control
roup (n  35) met LVAD criteria, but no device was
mplanted. There was a median survival of 11 days in
ontrols: 197 in the high-risk subjects and 467 days in the
ow-risk subjects. Twenty-five percent of high-risk patients
ere bridged to transplant; they had a higher post-implant
ortality.
The Tandem Heart (Cardiac Assist Inc., Pittsburgh,
ennsylvania) is a newly developed percutaneous LVAD
4). Twenty patients with acute myocardial infarction (MI)
reated with an intra-aortic balloon pump (IABP) were
ompared with 19 patients treated with the Tandem Heart.
verall, there was a greater improvement in hemodynamic
arameters in the LVAD group compared with IABP, but
o difference in 30-day mortality (45% for IABP, 39% fortFrom the Mayo Clinic, Rochester, Minnesota.VAD), largely due to LVAD complications. These newer
ercutaneous devices show promise, but further studies are
ecessary.
ardiac allograft vasculopathy. Cytomegalovirus (CMV)
nfection plays a role in the development of allograft
asculopathy. However, the relationship between the degree
f CMV infectious burden and allograft vasculopathy has
ot previously been examined. Potena et al. (5) presented
ata on 46 patients, suggesting that the degree of CMV
nfection is an independent predictor of intimal area in-
rease and progressive allograft vasculopathy.
Statin therapy is not yet routine in the pediatric heart
ransplant population. Mahle et al. (6) reviewed a total of
29 infants and children who had undergone 142 heart
ransplants at a median age of 7.3 years. In a multivariate
nalysis, the use of pravastatin was associated with a
ignificant reduction in the development of allograft vascu-
opathy (p  0.03). The authors concluded that statin
herapy should now be considered routine maintenance in
ediatric cardiac transplant patients.
ata from clinical trials. From the Candesartan in Heart
ailure (CHARM) study, the angiotensin receptor blocker
ARB) candesartan was examined for the prevention of type
I diabetes mellitus in patients with heart failure (7). A total
f 7,601 patients were randomized to 32 mg candesartan or
lacebo. Of this group, 5,436 had no diabetes mellitus at
tudy entry. There was a significant reduction in the
evelopment of new diabetes mellitus with patients receiv-
ng candesartan (163 [6%] of 2,715) compared with placebo
202 [7.4%] of 2,721). Candesartan may reduce the risk of
eveloping diabetes mellitus.
The Carvedilol Or Metoprolol European Trial (COMET)
ompared heart failure outcomes between carvedilol and
wice daily metoprolol. Adverse events were less common
ith carvedilol, including the risk of sudden death, MI,
nstable angina, stroke, heart failure, dyspnea, or shortness
f breath, as well as the development of diabetes and
ypokalemia. However, hypotension, dizziness, and syn-
ope were more common with carvedilol (8). Quality-of-life
mprovements in the carvedilol group were also noted, as
ompared with the metoprolol group (9). Patients on higher
oses of beta-blockers were found to be younger and have a
igher resting blood pressure and heart rate. Administration
f a target dose was an independent predictor of lower
ortality risk (10).
The Calcium Sensitizer or Inotrope or None in Low
utput Heart Failure (CASINO) study examined the novel
alcium channel sensitizer called levosimendan for the
reatment of low-output heart failure (11). This was a
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July 21, 2004:2A–6A ACC 2004 Annual Session Highlightsulticenter study of 227 patients with an LVEF of 35%,
ho were assigned to levosimendan (n  74), dobutamine
n  76), or placebo (n  77). The drug was infused for
4 h. The primary end point was a composite of death or
e-hospitalization due to heart failure worsening and was
eached at six months in 30.6% of the levosimendan group,
ompared with 52.7% of the dobutamine group and 48.1%
f the placebo group.
eart failure and anemia. Anemia in diastolic heart fail-
re is frequent and associated with a worse outcome,
ncreased brain natriuretic peptide (BNP) levels, and more
evere systolic dysfunction. Anker et al. (12), for the Effect
f Carvedilol on Survival in Severe Chronic Heart Failure
COPERNICUS) study, reported that anemia was an
ndependent risk factor for adverse outcome in severe heart
ailure. The mechanism may be due to blunted erythropoi-
tin production, as well as a defective iron supply (13).
ltered steroid metabolism with an increased cortisol/
ehydroepiandrosterone (DHEA) ratio is a strong predictor
f anemia in males with congestive heart failure (CHF)
14). Data from the Study of Anemia in a Heart Failure
opulation (STAMINA-HFP) registry suggested that ane-
ia is common in CHF seen in specialty and community
ardiology clinics (15) and is associated with a reduced
uality of life (16).
NP testing. The BNP testing continues to be of interest
or stratification of patients with heart failure. In the
reathing Not Properly multinational study, 227 patients
ith CHF were followed. There were 51 events, including
eath and re-admission. Patients with adverse events had
igher BNP values at admission and discharge, with fewer
dverse events in the patients with a greater degree of BNP
ecrease (17).
Data on non-terminal (NT) pro-BNP was presented by
itrovic et al. (18), who studied 523 patients with a mean
VEF of 25% and New York Heart Association (NYHA)
unctional class II to IV. The NT pro-BNP level was
ncreased as compared with controls and correlated with the
NP level, LVEF, end-diastolic volume, and systolic vol-
me and wall stress, but not with the stroke volume or
ardiac output. Nonterminal pro-BNP was also found to be
ignificantly higher in patients who died as compared with
hose who survived. Also, NT pro-BNP correlates well with
NP and is a predictor of mortality in CHF.
eta-blockers. Heart failure physicians usually titrate
atients up on angiotensin-converting enzyme (ACE)
nhibitors before beta-blockade. Krum et al. (19) ques-
ioned this strategy in a meta-analysis of available large
n 500), placebo-controlled studies. The results suggested
greater magnitude of prognostic benefit conferred by
eta-blockers compared with ACE inhibitors, supporting
arly introduction.
Massie et al. and the COreg HEart failure REgistry
COHERE) investigators (20) examined the characteristics
f heart failure patients by initiating carvedilol and whether shey relate to ejection fraction. It was found that age,
ercentage of women, hypertensive diabetics, and baseline
lood pressure all increase with increasing ejection fraction.
lower ejection fraction appears to be associated with a
igher NYHA functional class, a greater number of hospi-
alizations, and greater mortality.
Beta-blockers in the community are used at lower doses
han in clinical trials and when prescribed by cardiologists.
or the COHERE investigators, Fowler et al. (21) pre-
ented data showing that although carvedilol dosing in the
ommunity was lower than in trials and was more influenced
y NYHA functional class, at all doses, there appears to be
lower incidence of death and heart failure hospitalizations.
Howlett et al. (22) examined whether the mortality
enefit of beta-blockers is related to the initial heart rate. A
otal of 4,888 patients with a discharge diagnosis of heart
ailure from any Nova Scotia hospital were studied. Beta-
locker prescription at discharge was associated with a 37%
ower two-year mortality, regardless of the initial heart rate.
esynchronization therapy. Resynchronization therapy is
stablished in patients with heart failure and ventricular
yssynchrony. A substudy from MIRACLE, presented by
t. John Sutton et al. (23), examined whether reverse
emodeling varies with infarct location. Patients in NYHA
unctional class III and IV heart failure, with an LVEF
35% and with the presence of ventricular dyssynchrony,
nderwent implantation of the InSync biventricular pacing
ystem. An atrioventricular delay was optimized, and pa-
ients were randomized to no pacing or cardiac resynchro-
ization therapy. It was found that there were significant
eductions in left ventricular end-diastolic (LVEDV) and
eft ventricular end-systolic volume (LVESV) in patients
ho had an inferior MI (n  28; 43.2 and 43.1 cm3,
espectively). In patients in the anterior MI group (n  48),
hanges in LVEDV and LVESV were 1.6 and 5.3 cm3,
espectively. This was despite improvements in LVEF and
itral regurgitation in both groups. The investigators con-
luded that the infarct location determines the extent of
emodeling in heart failure patients treated with cardiac
esynchronization therapy.
se of cell therapy in CHF. This remains an evolving
rea. Which cell type to use has not yet been established,
nd the studies presented have reinforced this controversy.
erin et al. (24) examined transendocardial injection of
utologous bone marrow mononuclear cells. Fourteen pa-
ients with ischemic cardiomyopathy were treated with
ransendocardial injection of cells into a target area, defined
s a reversible defect by single-photon emission computed
omography (SPECT) with viability by electromechanical
oltage mapping. A control group of six patients had no
ntervention. In the injected area, there was no difference in
oltage at baseline and four months. However, there were
ignificant differences in voltage in the peri-infarct area. The
uthors concluded that this increase in voltage may repre-
ent expansion in myocardial viability. The same study
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ACC 2004 Annual Session Highlights July 21, 2004:2A–6Aroup found that within two months of stem-cell injection,
here were significant reductions in the total reversibility of
he defect (15% to 5%, p  0.022), as well as an improve-
ent in the ejection fraction (30% to 35%, p  0.02) and
YHA functional class (2.21 to 1.14) (25).
Dib et al. (26) presented the results of a multicenter study
n which autologous skeletal myoblast transplantation was
erformed at the time of coronary artery bypass grafting
CABG) in patients with a previous MI and LVEF 40%.
ll patients underwent a 2-g muscle biopsy to expand
yoblasts. Subsequently, 3 to 30 injections were performed
nto the infarct area with 10 to 300 million cells. A total of
2 patients underwent this procedure, combined with
ABG. Echocardiography, positron emission tomography,
nd magnetic resonance imaging studies showed viability in
he grafted scar, and there was an increase in LVEF from
4.8% to 33.9% (p  0.04) in 10 patients. The procedure
ppears to be feasible and safe, but it is unclear whether the
enefit was due to skeletal myoblast transplantation or
ABG.
yocarditis. Myocarditis following smallpox vaccination
as presented by Dr. Eckart from the Army Medical
enters (27). Fifty-three military personnel developed
robable acute myopericarditis following smallpox vaccina-
ion. In these patients, troponin I was elevated on presen-
ation (10.5  23.4 ng/ml) and remained elevated to a
imilar level for up to 48 h, with a peak troponin I level of
4.8  26.5 ng/ml at a median of 6.7 h. Creatine kinase
CK) and CK-MB were also elevated within 24 to 48 h,
ith a peak CK-MB level of 438  339 at a median of
.9 h. Vaccinial myocarditis may therefore present as
ustained elevation of cardiac enzymes for up to four days.
ypertrophic cardiomyopathy. Ommen et al. (28), from
he Mayo Clinic, examined the long-term effects of surgical
yectomy in 1,337 patients evaluated between 1983 and
001. This is the largest study examining this subject. Of
hese patients, 289 underwent isolated surgical myectomy
or LV outflow tract obstruction; 228 were managed with-
ut surgery; and 820 had nonobstructive hypertrophic car-
iomyopathy. Survival rates at 1, 5, and 10 years were 98%,
6%, and 83%, respectively, in the group that had under-
one myectomy, which is no different from the control
opulation of patients with nonobstructive hypertrophic
ardiomyopathy. Myectomy patients have a better survival
han nonoperated, obstructed patients. The authors con-
luded that myectomy reduces the excess mortality risk
ssociated with outflow tract obstruction.
The mechanism of systolic anterior motion of the mitral
alve following septal ablation was examined by Nesta et al.
29) from the Massachusetts General Hospital. The echo-
ardiograms of 30 patients were reviewed before and three
onths after septal ablation, and it was concluded that
ersistent systolic anterior motion was largely due to ante-
ior malposition of the mitral valve.Van Driest et al. from the Mayo Clinic (30) examined sarcomeric mutations in hypertrophic cardiomyopathy. The
requency spectrum and phenotype in patients with complex
enetic status (more than one sarcomeric mutation) was
xamined. Of 389 patients, 151 (38.8%) had at least one
utative pathogenic mutation. Eleven patients (2.8%) had
wo putative mutations, and these patients were younger at
iagnosis, with a greater degree of hypertrophy, and more
requently had an implantable cardioverter-defibrillator
ICD). Multiple sarcomeric mutations result in a greater
egree of hypertrophy and an earlier diagnosis of hypertro-
hic cardiomyopathy.
eripartum cardiomyopathy. Tallaj et al. (31), from Bir-
ingham, Alabama, examined outcomes in peripartum
ardiomyopathy in the current era, with a retrospective chart
eview from 1990 to 2000. Of 37 patients with peripartum
ardiomyopathy, 81% were in NYHA functional class III/
V, with an LVEF of 23  11%. Thirty-two patients were
reated with ACE inhibitors, nine with angiotensin receptor
lockers, 17 with beta-blockers, as well as digoxin (76%),
iuretics (89%), spironolactone (33%), nitrate (6%), and
arfarin (41%). Four patients underwent heart transplanta-
ion; one patient died; and one was lost to follow-up. Ninety
ercent (25 of 31) were in NYHA functional class I/II, with
n LVEF of 40  16% (42% of patients had normalized
heir ejection fraction). Although, historically, peripartum
ardiomyopathy does not have a good outcome, the prog-
osis appears to be significantly better than that previously
eported.
ate-breaking clinical trials. The WATCH study sought
o clarify the role of anticoagulation in CHF patients in
ormal sinus rhythm. The study was a three-arm, random-
zed trial of open-label warfarin (with an international
ormalized ratio maintained at 2.5 to 3.5) or double-
linded antiplatelet therapy with 162 mg aspirin or 75 mg
lopidogrel. All patients had an LVEF 35% with symp-
omatic CHF and ongoing treatment with ACE inhibitors
nd diuretics. A total of 1,587 patients were enrolled. There
as no significant difference in the primary end point of
ll-cause mortality and nonfatal MI or stroke. However,
here were a higher number of hospitalizations and exacer-
ations due to heart failure in the aspirin group and fewer
eart failure hospitalizations in the clopidogrel group. The
tudy reinforced the concept that the use of aspirin in
atients with heart failure treated with ACE inhibitors may
e deleterious.
The Sudden Cardiac Death in Heart Failure Trial (SCD-
eFT) study examined amiodarone or ICD therapy com-
ared with placebo in NYHA functional class II and III
HF. A total of 2,521 patients were enrolled from Septem-
er 1997 to July 2001, and followed until the end of October
003. The primary specific aim was all-cause mortality. The
hree arms were: 1) conventional CHF therapy and placebo;
) conventional CHF therapy and amiodarone; and 3)
onventional therapy and single-lead ICD. The five-year
urvival rates were 28.9% for the ICD group, 34.1% for the
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July 21, 2004:2A–6A ACC 2004 Annual Session Highlightsmiodarone group, and 35.8% for the placebo group. For
atients with NYHA functional class II or III CHF with an
VEF 35% on good background therapy, mortality for
he placebo-controlled patients was 7.2% per year over a
ve-year period, and a simple shock-only ICD decreased
ortality by 23%. Amiodarone, when used as a primary
reventative agent, does not improve survival.
The Defibrillator in Acute Myocardial Infarction Trial
DINAMIT) study examined prophylactic ICD therapy
arly after acute MI (4 to 40 days) with an LVEF35% and
vidence of impaired cardiac autonomic modulation. A total
f 674 patients were randomized, 332 of whom received an
CD; 65% of the patients were reperfused and 90% were
reated with optimal medical therapy. The primary aim was
ll-cause mortality, with a mean follow-up of 30 months.
here was no difference in the primary end point for
ptimal medical therapy (6.9%) or for medical therapy and
CD (7.5%). However, there was a decreased incidence of
rrhythmic death in the ICD group (1.5% vs. 3.5% annual
ortality). In addition, there was an increased incidence of
onarrhythmic death in the ICD group.
eprint requests and correspondence: Dr. Sudhir S. Kushwaha,
ayo Clinic, 200 First Street SW, Rochester, Minnesota 55905.
-mail: kushwaha.sudhir@mayo.edu.
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